# Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

> **NCT01609127** · PHASE2 · UNKNOWN · sponsor: **Genta Incorporated** · enrollment: 213 (estimated)

## Conditions studied

- Locally Advanced Non-resectable Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Tesetaxel
- **DRUG:** Tesetaxel
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01609127
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-05
- **Primary completion:** 2013-09
- **Final completion:** 2014-07
- **Target enrollment:** 213 (ESTIMATED)
- **Last updated:** 2012-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01609127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01609127, "Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01609127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*